Table 3.
Univariate analysis for overall survival
| Characteristics | HR (95 % CI) | p-value |
|---|---|---|
| Location of primary tumor (rectum vs colon) | 0.531 (0.212–1.333) | 0.178 |
| Age (≥65 vs <65) | 7.492 (2.941–9.084) | <0.001 |
| Sex (female vs male) | 2.038 (0.908–4.578) | 0.085 |
| Neoadjuvant chemotherapy (Yes vs No) | 1.114 (0.460–2.698) | 0.811 |
| Tumor grade (moderate/poor vs well) | 1.332 (0.312–5.693) | 0.698 |
| T stage (T4 vs T1-3) | 4.324 (1.857–10.068) | 0.001 |
| N stage (N2 vs N0,1) | 1.906 (0.854–4.251) | 0.115 |
| Resection site | ||
| Liver | 1 | |
| Lung | 0.311 (0.041–2.335) | 0.256 |
| Others (ovary, uterus, bladder) | 1.036 (0.345–3.108) | 0.950 |
| Use of Cetuximab at 1st post-operative chemotherapy (Yes vs No) | 3.777 (0.850–16.779) | 0.081 |
| Use of Bevacizumab at 1st post-operative chemotherapy (Yes vs No) | 0.899 (0.267–3.027) | 0.863 |
| KRAS (mutation vs mutation) | 0.500(0.198–1.267) | 0.144 |
| KRAS | ||
| Wild | 1 | |
| 12th | 0.330 (0.076–1.428) | 0.138 |
| 13th | 0.675 (0.227–2.010) | 0.481 |
Abbreviations: CI confidence interval, A.A amino acid, HR hazard ratio
Factors of statistical significance (p < 0.10) in univariate analysis presented with boldface